Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 2/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.32 |
| ▸ | VEGFA | P15692 | 2/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5381993 | 0.92 | CYP3A4 (0.47) | CYP3A4CYP2C9CYP2C19THRATHRB | |
| SCHEMBL5381986 | 0.92 | CYP3A4 (0.47) | CYP3A4THRATHRBDAOAKR1B1 | |
| SCHEMBL5367067 | 0.88 | CYP3A4 (0.43) | CYP3A4CYP2C9CYP2C19THRATHRB | |
| SCHEMBL5366918 | 0.86 | CYP3A4 (0.47) | CYP3A4THRATHRBAKR1B1 | |
| SCHEMBL5364926 | 0.85 | CYP3A4 (0.54) | CYP3A4THRATHRB | |
| SCHEMBL5377385 | 0.85 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP2C19THRATHRB | |
| SCHEMBL5365366 | 0.85 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP2C19VEGFAEPAS1 | |
| SCHEMBL5368714 | 0.83 | CYP3A4 (0.53) | CYP3A4THRATHRBDAOAKR1B1 | |
| SCHEMBL5376890 | 0.82 | P2RX3 (0.40) | CYP3A4CYP2C9CYP2C19DAOEPAS1 | |
| SCHEMBL5373613 | 0.81 | CYP3A4 (0.51) | CYP3A4THRATHRBDAOAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189718-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189718-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189718-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR1A, POLR2A, POLR2E | CYP3A4 264/4885CYP2C9 808/4885CYP2C19 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.